絞り込み

16645

広告

Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis.

著者 Shen NN , Zhang XM , Le KJ , Wei AH , Wu Y , Gu ZC
Medicine (Baltimore).2019 Jun ; 98(26):e16194.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Medical

Miscellaneous

Atrial fibrillation (AF) is increasingly prevalent in chronic kidney disease (CKD) patients. The efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in AF and CKD patients remains unknown. This systematic review and meta-analysis will mainly assess net clinical benefit (NCB) property of NOACs versus warfarin in patients with AF and CKD by a pooled-analysis.
PMID: 31261559 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード